Visiting fellow Erasmus School of Health Policy & Management Health Technology Assessment (HTA)
- Location
- Burg. Oudlaan 50, Rotterdam
- s.degroot@eshpm.eur.nl
More information
‹ Back to overview
Profile
Saskia de Groot completed the bachelor programme Health Policy & Management at the Erasmus University Rotterdam in 2007. In 2009, she obtained her master’s degree in Health Economics, Policy & Law. She continued her studies by enrolling in a research master programme in Health Sciences with a specialisation in Clinical Epidemiology at the Netherlands Institute for Health Sciences (2009–2011).
During her studies at the Erasmus University Rotterdam, she started working as a research assistant at the institute of Health Policy & Management. After obtaining her master's degree, she started working on a PhD project on the evaluation of clinical and economic outcomes of new therapies for metastatic renal cell carcinoma at the same institute. She finished her PhD thesis in 2016. Besides her research on conditional funding of expensive inpatient drugs, she worked on various advisory projects, including different projects for the Dutch National Health Care Institute.
- B Grigore, O Ciani, F Dams, C Federici, Saskia Groot, M Möllenkamp, S Rabbe, K Shatrov, A Zemplenyi & R Taylor (2020) - Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines - Pharmacoeconomics (Print), 38, 1055-1070 - doi: 10.1007/s40273-020-00935-1
- Valerie Wester, Saskia Groot, Tim Kanters, L Wagner, J Ardesch, Isaac Corro Ramos, MJ Enders-Slegers, M de Ruiter, S le Cessie, Jeanine Los, Greg Papageorgiou, Job Exel & Matthijs Versteegh (2020) - Evaluating the Effectiveness and Cost-Effectiveness of Seizure Dogs in Persons With Medically Refractory Epilepsy in the Netherlands: Study Protocol for a Stepped Wedge Randomized Controlled Trial (EPISODE) - Frontiers in Neurology, 11 (3) - doi: 10.3389/fneur.2020.00003 - [link]
- Saskia Groot, Ken Redekop, Matthijs Versteegh, Stefan Sleijfer, E Oosterwijk, LALM Kiemeney & Carin Groot (2018) - Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma - Quality of Life Research, 27, 115-124 - doi: 10.1007/s11136-017-1704-4
- Silvia Verelst, Hedwig Blommestein, Saskia Groot, S Gonzalez-McQuire, L DeCosta, JB de Raad, Carin Groot & Pieter Sonneveld (2018) - Long-term Outcomes in Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS) - HemaSphere, 2 (4) - doi: 10.1097/HS9.0000000000000045
- Saskia Groot, CF (Catherine) Enters-Weijnen, PH Geelhoed-Duijvestijn & Tim Kanters (2018) - A cost of illness study of hypoglycaemic events in insulin-treated diabetes in the Netherlands - BMJ Open, 8 (3) - doi: 10.1136/bmjopen-2017-019864 - [link]
- Nasuh Buyukkaramikli, Saskia Groot, R Riemsma, D Fayter, N Armstrong, P Portegijs, S Duffy, J Kleijnen & Maiwenn Al (2018) - Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal - Pharmacoeconomics (Print) - doi: 10.1007/s40273-018-0708-4
- Saskia Groot, Hedwig Blommestein, Ken Redekop, Stefan Sleijfer, L Kiemeney, E Oosterwijk & Carin Groot (2017) - Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments - PLoS One (print), 12 (5) - doi: 10.1371/journal.pone.0177364
- NC Büyükkaramikli, Saskia Groot, D Fayter, R Wolff, N Armstrong, L Stirk, G Worthy, Fernando Albuquerque de Almeida, J Kleijnen & Maiwenn Al (2017) - Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal - Pharmacoeconomics (Print) - doi: 10.1007/s40273-017-0581-6
- Saskia Groot, Ken Redekop, Stefan Sleijfer, E Oosterwijk, A Bex, LALM Kiemeney & Carin Groot (2016) - Survival in patients with primary metastatic renal cell carcinoma treated with sunitinib with or without previous cytoreductive nephrectomy: Results from a population-based registry - Urology, 95, 121-127 - doi: 10.1016/j.urology.2016.04.042
- Saskia Groot, Stefan Sleijfer, Ken Redekop, E Oosterwijk, JB Haanen, LALM Kiemeney & Carin Groot (2016) - Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry - BMC Cancer, 16, 364 - doi: 10.1186/s12885-016-2395-x
- Saskia Groot, Naomi Linden, Margreet Franken, Hedwig Blommestein, Brenda Leeneman, Ellen Rooijen, JJM van der Hoeven, MW Wouters, Hans Westgeest & Carin Groot (2016) - Balancing the optimal and the feasible: A practical guide for setting up patient registries for the collection of real-world data for health care decision making based on Dutch experiences - Value in Health - doi: 10.1016/j.jval.2016.02.007
- Hedwig Blommestein, Saskia Groot, MJ Aarts, P (Pepijn) Vemer, R de Vries, AFM Abeelen, EFM Posthuma & Carin Groot (2016) - Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands - Leukemia Research, 50, 37-45 - doi: 10.1016/j.leukres.2016.09.005
- Saskia Groot, AJ Rijnsburger, Matthijs Versteegh, JM Heymans, S Kleijnen, Ken Redekop & I Verstijnen (2015) - Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers - BMJ Open, 5 - doi: 10.1136/bmjopen-2014-007241
- Hedwig Blommestein, Silvia Verelst, Saskia Groot, PC Huijgens, Pieter Sonneveld & Carin Groot (2015) - A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model - European Journal of Haematology, 96 (2), 198-208 - doi: 10.1111/ejh.12571
- Chantal Gils, Saskia Groot, Siok Swan Tan, Ken Redekop, M Koopman, CJ Punt & Carin Groot (2014) - Real-world resource use and costs of adjuvant treatment for stage III colon cancer - European Journal of Cancer Care, 24 (3), 321-332 - doi: 10.1111/ecc.12154
- Chantal Gils, Saskia Groot, Ken Redekop, M Koopman, CJA Punt & Carin Groot (2013) - Real-World Cost-Effectiveness of Oxaliplatin in Stage III Colon Cancer: A Synthesis of Clinical Trial and Daily Practice Evidence - Pharmacoeconomics (Print), 31 (8), 703-718 - doi: 10.1007/s40273-013-0061-6
- Carin Groot, Saskia Groot & Adri Steenhoek (2010) - The economics of improved cancer survival rates: better outcomes, higher costs - Expert review of pharmacoeconomics & outcomes research, 10 (3), 283-292 - doi: 10.1586/erp.10.27
- Gimon Graaf, Saskia Groot, Valerie Wester, Heleen Vellekoop, Matthijs Versteegh & M Rutten-van Molken (2019) - WAARDEBEPALING, IMPLEMENTATIE EN BEKOSTIGING VAN VOORSPELLENDE TESTEN IN NEDERLAND - [link] - ZonMw
- B Grigore, O Ciani, F Dams, C Federici, Saskia Groot, M Möllenkamp, S Rabbe, K Shatrov, A Zemplenyi & R Taylor (2020) - Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines - Pharmacoeconomics (Print), 38, 1055-1070 - doi: 10.1007/s40273-020-00935-1
- Valerie Wester, Saskia Groot, Tim Kanters, L Wagner, J Ardesch, Isaac Corro Ramos, MJ Enders-Slegers, M de Ruiter, S le Cessie, Jeanine Los, Greg Papageorgiou, Job Exel & Matthijs Versteegh (2020) - Evaluating the Effectiveness and Cost-Effectiveness of Seizure Dogs in Persons With Medically Refractory Epilepsy in the Netherlands: Study Protocol for a Stepped Wedge Randomized Controlled Trial (EPISODE) - Frontiers in Neurology, 11 (3) - doi: 10.3389/fneur.2020.00003 - [link]
- Saskia Groot, Ken Redekop, Matthijs Versteegh, Stefan Sleijfer, E Oosterwijk, LALM Kiemeney & Carin Groot (2018) - Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma - Quality of Life Research, 27, 115-124 - doi: 10.1007/s11136-017-1704-4
- Silvia Verelst, Hedwig Blommestein, Saskia Groot, S Gonzalez-McQuire, L DeCosta, JB de Raad, Carin Groot & Pieter Sonneveld (2018) - Long-term Outcomes in Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS) - HemaSphere, 2 (4) - doi: 10.1097/HS9.0000000000000045
- Saskia Groot, CF (Catherine) Enters-Weijnen, PH Geelhoed-Duijvestijn & Tim Kanters (2018) - A cost of illness study of hypoglycaemic events in insulin-treated diabetes in the Netherlands - BMJ Open, 8 (3) - doi: 10.1136/bmjopen-2017-019864 - [link]
- Nasuh Buyukkaramikli, Saskia Groot, R Riemsma, D Fayter, N Armstrong, P Portegijs, S Duffy, J Kleijnen & Maiwenn Al (2018) - Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal - Pharmacoeconomics (Print) - doi: 10.1007/s40273-018-0708-4
- Saskia Groot, Hedwig Blommestein, Ken Redekop, Stefan Sleijfer, L Kiemeney, E Oosterwijk & Carin Groot (2017) - Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments - PLoS One (print), 12 (5) - doi: 10.1371/journal.pone.0177364
- NC Büyükkaramikli, Saskia Groot, D Fayter, R Wolff, N Armstrong, L Stirk, G Worthy, Fernando Albuquerque de Almeida, J Kleijnen & Maiwenn Al (2017) - Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal - Pharmacoeconomics (Print) - doi: 10.1007/s40273-017-0581-6
- Saskia Groot, Ken Redekop, Stefan Sleijfer, E Oosterwijk, A Bex, LALM Kiemeney & Carin Groot (2016) - Survival in patients with primary metastatic renal cell carcinoma treated with sunitinib with or without previous cytoreductive nephrectomy: Results from a population-based registry - Urology, 95, 121-127 - doi: 10.1016/j.urology.2016.04.042
- Saskia Groot, Stefan Sleijfer, Ken Redekop, E Oosterwijk, JB Haanen, LALM Kiemeney & Carin Groot (2016) - Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry - BMC Cancer, 16, 364 - doi: 10.1186/s12885-016-2395-x
- Saskia Groot, Naomi Linden, Margreet Franken, Hedwig Blommestein, Brenda Leeneman, Ellen Rooijen, JJM van der Hoeven, MW Wouters, Hans Westgeest & Carin Groot (2016) - Balancing the optimal and the feasible: A practical guide for setting up patient registries for the collection of real-world data for health care decision making based on Dutch experiences - Value in Health - doi: 10.1016/j.jval.2016.02.007
- Hedwig Blommestein, Saskia Groot, MJ Aarts, P (Pepijn) Vemer, R de Vries, AFM Abeelen, EFM Posthuma & Carin Groot (2016) - Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands - Leukemia Research, 50, 37-45 - doi: 10.1016/j.leukres.2016.09.005
- Saskia Groot, AJ Rijnsburger, Matthijs Versteegh, JM Heymans, S Kleijnen, Ken Redekop & I Verstijnen (2015) - Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers - BMJ Open, 5 - doi: 10.1136/bmjopen-2014-007241
- Hedwig Blommestein, Silvia Verelst, Saskia Groot, PC Huijgens, Pieter Sonneveld & Carin Groot (2015) - A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model - European Journal of Haematology, 96 (2), 198-208 - doi: 10.1111/ejh.12571
- Chantal Gils, Saskia Groot, Siok Swan Tan, Ken Redekop, M Koopman, CJ Punt & Carin Groot (2014) - Real-world resource use and costs of adjuvant treatment for stage III colon cancer - European Journal of Cancer Care, 24 (3), 321-332 - doi: 10.1111/ecc.12154
- Chantal Gils, Saskia Groot, Ken Redekop, M Koopman, CJA Punt & Carin Groot (2013) - Real-World Cost-Effectiveness of Oxaliplatin in Stage III Colon Cancer: A Synthesis of Clinical Trial and Daily Practice Evidence - Pharmacoeconomics (Print), 31 (8), 703-718 - doi: 10.1007/s40273-013-0061-6
- Carin Groot, Saskia Groot & Adri Steenhoek (2010) - The economics of improved cancer survival rates: better outcomes, higher costs - Expert review of pharmacoeconomics & outcomes research, 10 (3), 283-292 - doi: 10.1586/erp.10.27
- B Grigore, O Ciani, F Dams, C Federici, Saskia Groot, M Möllenkamp, S Rabbe, K Shatrov, A Zemplenyi & R Taylor (2020) - Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines - Pharmacoeconomics (Print), 38, 1055-1070 - doi: 10.1007/s40273-020-00935-1
- Valerie Wester, Saskia Groot, Tim Kanters, L Wagner, J Ardesch, Isaac Corro Ramos, MJ Enders-Slegers, M de Ruiter, S le Cessie, Jeanine Los, Greg Papageorgiou, Job Exel & Matthijs Versteegh (2020) - Evaluating the Effectiveness and Cost-Effectiveness of Seizure Dogs in Persons With Medically Refractory Epilepsy in the Netherlands: Study Protocol for a Stepped Wedge Randomized Controlled Trial (EPISODE) - Frontiers in Neurology, 11 (3) - doi: 10.3389/fneur.2020.00003 - [link]
- Saskia Groot, Ken Redekop, Matthijs Versteegh, Stefan Sleijfer, E Oosterwijk, LALM Kiemeney & Carin Groot (2018) - Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma - Quality of Life Research, 27, 115-124 - doi: 10.1007/s11136-017-1704-4
- Silvia Verelst, Hedwig Blommestein, Saskia Groot, S Gonzalez-McQuire, L DeCosta, JB de Raad, Carin Groot & Pieter Sonneveld (2018) - Long-term Outcomes in Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS) - HemaSphere, 2 (4) - doi: 10.1097/HS9.0000000000000045
- Saskia Groot, CF (Catherine) Enters-Weijnen, PH Geelhoed-Duijvestijn & Tim Kanters (2018) - A cost of illness study of hypoglycaemic events in insulin-treated diabetes in the Netherlands - BMJ Open, 8 (3) - doi: 10.1136/bmjopen-2017-019864 - [link]
- Nasuh Buyukkaramikli, Saskia Groot, R Riemsma, D Fayter, N Armstrong, P Portegijs, S Duffy, J Kleijnen & Maiwenn Al (2018) - Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal - Pharmacoeconomics (Print) - doi: 10.1007/s40273-018-0708-4
- Saskia Groot, Hedwig Blommestein, Ken Redekop, Stefan Sleijfer, L Kiemeney, E Oosterwijk & Carin Groot (2017) - Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments - PLoS One (print), 12 (5) - doi: 10.1371/journal.pone.0177364
- NC Büyükkaramikli, Saskia Groot, D Fayter, R Wolff, N Armstrong, L Stirk, G Worthy, Fernando Albuquerque de Almeida, J Kleijnen & Maiwenn Al (2017) - Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal - Pharmacoeconomics (Print) - doi: 10.1007/s40273-017-0581-6
- Saskia Groot, Ken Redekop, Stefan Sleijfer, E Oosterwijk, A Bex, LALM Kiemeney & Carin Groot (2016) - Survival in patients with primary metastatic renal cell carcinoma treated with sunitinib with or without previous cytoreductive nephrectomy: Results from a population-based registry - Urology, 95, 121-127 - doi: 10.1016/j.urology.2016.04.042
- Saskia Groot, Stefan Sleijfer, Ken Redekop, E Oosterwijk, JB Haanen, LALM Kiemeney & Carin Groot (2016) - Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry - BMC Cancer, 16, 364 - doi: 10.1186/s12885-016-2395-x
- Saskia Groot, Naomi Linden, Margreet Franken, Hedwig Blommestein, Brenda Leeneman, Ellen Rooijen, JJM van der Hoeven, MW Wouters, Hans Westgeest & Carin Groot (2016) - Balancing the optimal and the feasible: A practical guide for setting up patient registries for the collection of real-world data for health care decision making based on Dutch experiences - Value in Health - doi: 10.1016/j.jval.2016.02.007
- Hedwig Blommestein, Saskia Groot, MJ Aarts, P (Pepijn) Vemer, R de Vries, AFM Abeelen, EFM Posthuma & Carin Groot (2016) - Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands - Leukemia Research, 50, 37-45 - doi: 10.1016/j.leukres.2016.09.005
- Saskia Groot, AJ Rijnsburger, Matthijs Versteegh, JM Heymans, S Kleijnen, Ken Redekop & I Verstijnen (2015) - Which factors may determine the necessary and feasible type of effectiveness evidence? A mixed methods approach to develop an instrument to help coverage decision-makers - BMJ Open, 5 - doi: 10.1136/bmjopen-2014-007241
- Hedwig Blommestein, Silvia Verelst, Saskia Groot, PC Huijgens, Pieter Sonneveld & Carin Groot (2015) - A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model - European Journal of Haematology, 96 (2), 198-208 - doi: 10.1111/ejh.12571
- Chantal Gils, Saskia Groot, Siok Swan Tan, Ken Redekop, M Koopman, CJ Punt & Carin Groot (2014) - Real-world resource use and costs of adjuvant treatment for stage III colon cancer - European Journal of Cancer Care, 24 (3), 321-332 - doi: 10.1111/ecc.12154
- Chantal Gils, Saskia Groot, Ken Redekop, M Koopman, CJA Punt & Carin Groot (2013) - Real-World Cost-Effectiveness of Oxaliplatin in Stage III Colon Cancer: A Synthesis of Clinical Trial and Daily Practice Evidence - Pharmacoeconomics (Print), 31 (8), 703-718 - doi: 10.1007/s40273-013-0061-6
- Carin Groot, Saskia Groot & Adri Steenhoek (2010) - The economics of improved cancer survival rates: better outcomes, higher costs - Expert review of pharmacoeconomics & outcomes research, 10 (3), 283-292 - doi: 10.1586/erp.10.27
- Gimon Graaf, Saskia Groot, Valerie Wester, Heleen Vellekoop, Matthijs Versteegh & M Rutten-van Molken (2019) - WAARDEBEPALING, IMPLEMENTATIE EN BEKOSTIGING VAN VOORSPELLENDE TESTEN IN NEDERLAND - [link] - ZonMw
- Gimon Graaf, Saskia Groot, Valerie Wester, Heleen Vellekoop, Matthijs Versteegh & M Rutten-van Molken (2019) - WAARDEBEPALING, IMPLEMENTATIE EN BEKOSTIGING VAN VOORSPELLENDE TESTEN IN NEDERLAND - [link] - ZonMw